Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 94
Filtrar
Mais filtros

Bases de dados
País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
1.
Eksp Onkol ; 8(2): 35-8, 70, 1986.
Artigo em Russo | MEDLINE | ID: mdl-3698881

RESUMO

It is shown that prodigiosan is an inductor of synthesis of the substances with the thymosin-like activity. The suggestion about inhibition of 3-methylcholanthrene-induced blastomogenesis by prodigiosan which is mediated by the substances with the thymosin-like activity and interferon is discussed. We present the hypothetical diagram of the development of the above mentioned mechanism. The significance of the obtained findings for elaboration of the immunotherapy is discussed.


Assuntos
Indutores de Interferon , Neoplasias Experimentais/induzido quimicamente , Polissacarídeos Bacterianos/uso terapêutico , Prodigiozan/uso terapêutico , Timosina/biossíntese , Animais , Avaliação Pré-Clínica de Medicamentos , Sinergismo Farmacológico , Metilcolantreno , Camundongos , Neoplasias Experimentais/tratamento farmacológico , Neoplasias Experimentais/mortalidade , Tamanho do Órgão/efeitos dos fármacos , Ratos , Baço/efeitos dos fármacos , Timectomia , Timosina/sangue , Timo/efeitos dos fármacos , Fatores de Tempo
2.
Radiats Biol Radioecol ; 34(4-5): 582-6, 1994.
Artigo em Russo | MEDLINE | ID: mdl-7951888

RESUMO

It was shown in experiments with mice and dogs that bacterial preparations (vaccinum proteus, prodigiosanum, bificolum and bificolum-f) administered before or after gamma-irradiation have a stimulating effect on hemopoiesis. It is supposed that bacterial polysaccharides play an important role in this action.


Assuntos
Produtos Biológicos/uso terapêutico , Hematopoese/efeitos dos fármacos , Lesões Experimentais por Radiação/terapia , Doença Aguda , Animais , Vacinas Bacterianas/uso terapêutico , Bacteriocinas/uso terapêutico , Cães , Relação Dose-Resposta à Radiação , Camundongos , Prodigiozan/uso terapêutico , Proteus/imunologia , Lesões Experimentais por Radiação/sangue , Fatores de Tempo
3.
Vestn Ross Akad Med Nauk ; (5): 36-41, 1996.
Artigo em Russo | MEDLINE | ID: mdl-8924825

RESUMO

The effects of hepatotropic growth factors (HGFs) and phospholipid drugs on the recovery of functions and the regeneration of the rat liver were studied in CC14-induced toxic damage and after partial hepatectomy (PHE). HGFs isolated from the cytoplasmic cells of the regenerating liver, as well as from the liver of the animals given prodigiozan and from the media taken after culturing the explants of the regenerating liver were found to stimulate DNA synthesis and hepatocytic proliferation following PHE and in the cirrhotic liver. Prodigiozan was shown to induce the formation of HGFs not only in the rat liver following PHE, but in the liver of intact animals. It was established that the covalently binding complex of albumin and bilirubin stimulated the synthesis of proteins and DNA in the regenerating liver, but non-covalently binding complex inhibited these processes. When CC14 was administered to the animals, the two complexes enhanced the reparative synthesis of DNA, without changing the level of replicating synthesis, the non-covalently binding complex completely eliminating the single-strand breaks in DNA. Phospholipid agents containing soybean and sunflower phosphatidylcholines increased the synthesis of RNA and albumin, which were decreased due to exposure to CC14 and had the property of stimulating the synthesis of total DNA and considerably enhancing that of mitochondrial DNA.


Assuntos
Antibacterianos/farmacologia , Doença Hepática Induzida por Substâncias e Drogas/tratamento farmacológico , Hepatectomia , Fator de Crescimento de Hepatócito/farmacologia , Regeneração Hepática/efeitos dos fármacos , Fígado/efeitos dos fármacos , Fosfatidilcolinas/farmacologia , Prodigiozan/farmacologia , Animais , Antibacterianos/uso terapêutico , Tetracloreto de Carbono/toxicidade , Doença Hepática Induzida por Substâncias e Drogas/etiologia , DNA/biossíntese , Helianthus , Fator de Crescimento de Hepatócito/uso terapêutico , Fígado/metabolismo , Fígado/fisiologia , Cirrose Hepática Experimental/cirurgia , Fosfatidilcolinas/uso terapêutico , Prodigiozan/uso terapêutico , RNA/biossíntese , Ratos , Glycine max
4.
Artigo em Russo | MEDLINE | ID: mdl-2870596

RESUMO

Experiments on 575 noninbred white mice have revealed that the nonspecific resistance of the animals to type A C. perfringens toxin can be enhanced by the administration of Prodigiosan, a commercial immunostimulating agent. Prodigiosan, introduced in 3-4 injections (the last one made 24 hours before intoxication) has been found to enhance the resistance of the animals to the subcutaneous injection of type A C. perfringens toxin by 40-60% and to its intraperitoneal injection by 60-97%.


Assuntos
Adjuvantes Imunológicos/uso terapêutico , Toxinas Bacterianas/imunologia , Proteínas de Ligação ao Cálcio , Clostridium perfringens , Gangrena Gasosa/imunologia , Polissacarídeos Bacterianos/uso terapêutico , Prodigiozan/uso terapêutico , Fosfolipases Tipo C , Animais , Toxinas Bacterianas/antagonistas & inibidores , Avaliação Pré-Clínica de Medicamentos , Resistência a Medicamentos , Gangrena Gasosa/tratamento farmacológico , Gangrena Gasosa/mortalidade , Imunidade Inata/efeitos dos fármacos , Camundongos , Fatores de Tempo
5.
Artigo em Russo | MEDLINE | ID: mdl-2385993

RESUMO

The influence of prodigiosan, salmosan, polyribonate and levamisole on the body nonspecific and specific resistance to S. typhi strain 4446 has been studied. Prodigiosan and salmosan have proved to be the most effective. The injection of these compounds simultaneously with typhoid vaccine (both chemical adsorbed vaccine and alcohol-treated vaccine, enriched with Vi-antigen) significantly increases the survival rate of immunized animals (by 35-45%), elevates the resistance index (1.5- to 2.3-fold) and the effectiveness index of the vaccine (17- to 32-fold) in comparison with the controls. Besides, prodigiosan and salmosan alone are capable of increasing nonspecific resistance to S. typhi strain 4446, which is manifested by an increase of the survival rate of stimulated animals by 61.87%. Proceeding from the results thus obtained, the possibility of good prospects for prodigiosan and salmosan in the prophylaxis of typhoid fever in humans may be inferred.


Assuntos
Adjuvantes Imunológicos/uso terapêutico , Febre Tifoide/prevenção & controle , Animais , Avaliação Pré-Clínica de Medicamentos , Imunidade Inata/efeitos dos fármacos , Imunidade Inata/imunologia , Masculino , Camundongos , Compostos Orgânicos , Polissacarídeos Bacterianos/uso terapêutico , Prodigiozan/uso terapêutico , Salmonella typhi/efeitos dos fármacos , Salmonella typhi/imunologia , Febre Tifoide/imunologia , Febre Tifoide/mortalidade , Vacinas Tíficas-Paratíficas/imunologia
6.
Artigo em Russo | MEDLINE | ID: mdl-3364072

RESUMO

The immune and allergic status of patients with acute viral hepatitides A and B after treatment with prodigiosan, a bacterial lipopolysaccharide preparation, was studied. The drug produced as stimulating effect on cell-mediated and humoral immunity. The development of delayed specific drug sensitization was registered in two-thirds of the patients, which correlated with the regression of clinicobiochemical manifestations of hepatitis.


Assuntos
Hepatite A/imunologia , Hepatite B/imunologia , Hipersensibilidade Tardia/imunologia , Polissacarídeos Bacterianos/uso terapêutico , Prodigiozan/uso terapêutico , Adolescente , Adulto , Formação de Anticorpos/efeitos dos fármacos , Terapia Combinada , Convalescença , Hepatite A/complicações , Hepatite A/tratamento farmacológico , Hepatite B/complicações , Hepatite B/tratamento farmacológico , Humanos , Hipersensibilidade Tardia/tratamento farmacológico , Hipersensibilidade Tardia/etiologia , Imunidade Celular/efeitos dos fármacos , Pessoa de Meia-Idade
7.
Eksp Klin Farmakol ; 58(5): 9-12, 1995.
Artigo em Russo | MEDLINE | ID: mdl-8704600

RESUMO

The experiments carried out on mongrel male mice showed that bacterial lipopolysaccharide Prodigiozan inhibit the activity of P-450-dependent monooxygenases of the liver, thus changing the activity of antidepressants--amitriptyline and imipraminum. The data on biological activity were tested in "tail suspension" test. Prodigiozan exhibited no central effect. Changes in biotransformation processes after single administration of both drugs resulted in the delay and prolongation of the effect. Prodigiozan prevents the induction of microsomal enzymes caused by antidepressants. Amitriptyline do not affect the immunostimulating action of prodigiozan, whereas imipraminum inhibited prodigiozan activity.


Assuntos
Adjuvantes Imunológicos/farmacologia , Amitriptilina/farmacologia , Antidepressivos Tricíclicos/farmacologia , Imipramina/farmacologia , Prodigiozan/farmacologia , Adjuvantes Imunológicos/uso terapêutico , Amitriptilina/toxicidade , Animais , Antidepressivos Tricíclicos/toxicidade , Relação Dose-Resposta a Droga , Avaliação Pré-Clínica de Medicamentos , Interações Medicamentosas , Imipramina/toxicidade , Masculino , Camundongos , Prodigiozan/uso terapêutico , Infecções por Pseudomonas/tratamento farmacológico , Infecções por Pseudomonas/mortalidade , Sono/efeitos dos fármacos , Fatores de Tempo
8.
Antibiot Khimioter ; 33(2): 131-4, 1988 Feb.
Artigo em Russo | MEDLINE | ID: mdl-3377603

RESUMO

The effect of nonsteroid antiinflammatory drugs (NAID) such as voltaren, acetylsalicylic acid, indometacin and naproxen on the efficacy of immunostimulators in treatment of infections caused by Proteus and Staphylococcus was studied. It was shown that except naproxen the NAID were capable of decreasing resistance to Proteus infections. Acetylsalicylic acid increased resistance to staphylococcal infections. The rest of the drugs did not change it. Prodigiozan increased resistance to the infections at the background of the NAID. However, volteran and indometacin lowered its effect in infections caused by Proteus. Levamisol stimulated resistance of mice to the infections at the background of volteran and increased resistance to Proteus infections lowered by acetylsalicylic acid. Methyluracyl was not able to increase resistance to the infections at the background of the NAID. It only increased resistance to Proteus infections lowered by acetylsalicylic acid. Levamisol and methyluracyl did not as a rule increase efficacy of antibiotic therapy at the background of the NAID.


Assuntos
Anti-Inflamatórios não Esteroides/uso terapêutico , Levamisol/uso terapêutico , Polissacarídeos Bacterianos/uso terapêutico , Prodigiozan/uso terapêutico , Infecções por Proteus/tratamento farmacológico , Uracila/análogos & derivados , Adjuvantes Imunológicos , Animais , Interações Medicamentosas , Quimioterapia Combinada , Feminino , Masculino , Camundongos , Infecções por Proteus/imunologia , Uracila/uso terapêutico
10.
Antibiot Khimioter ; 33(7): 532-5, 1988 Jul.
Artigo em Russo | MEDLINE | ID: mdl-3056303

RESUMO

The effect of immunomodulating therapy of adjuvant disease in rats with cyclophosphamide, prodigiozan and their combinations on infection resistance, weight of the lymphoid organs and leukocyte counts in peripheral blood, as well as the effect of prodigiozan on acute toxicity of cyclophosphamide in intact mice and mice exposed to the Freund's complete adjuvant (FCA) was studied. Prodigiozan did not increase acute toxicity of cyclophosphamide in the intact mice. It lowered the cyclophosphamide toxicity at the background of the FCA and decreased the levels of leukopenia induced by the immunosuppressor in the rats with adjuvant arthritis. It was shown on the models of local infectious inflammation caused by Proteus and lethal sepsis due to P. aeruginosa that the combined use of prodigiozan and cyclophosphamide resulted in correction of the infection resistance impairment induced by both the arthritis development and the immunosuppressor administration.


Assuntos
Adjuvantes Imunológicos , Artrite Experimental/tratamento farmacológico , Artrite/tratamento farmacológico , Ciclofosfamida/uso terapêutico , Polissacarídeos Bacterianos/uso terapêutico , Prodigiozan/uso terapêutico , Animais , Artrite Experimental/imunologia , Ciclofosfamida/toxicidade , Avaliação Pré-Clínica de Medicamentos , Interações Medicamentosas , Quimioterapia Combinada , Imunidade Inata/efeitos dos fármacos , Dose Letal Mediana , Infecções por Proteus/imunologia , Infecções por Proteus/prevenção & controle , Proteus mirabilis , Infecções por Pseudomonas/imunologia , Infecções por Pseudomonas/prevenção & controle , Ratos
11.
Ter Arkh ; 56(10): 14-7, 1984.
Artigo em Russo | MEDLINE | ID: mdl-6335305

RESUMO

Twenty-seven patients with chronic obstructive bronchitis and 47 patients with chronic non-obstructive bronchitis were subjected to subpopulation analysis of peripheral blood immunocompetent cells. Statistically significant changes in the content of T mu and T gamma cells, killer and suppressor activity of lymphocytes were discovered in patients with chronic bronchitis. One of the immunological differences between chronic obstructive and chronic non-obstructive bronchitis lies in the activity of Con A-induced suppressors, which is appreciably lowered in patients with chronic obstructive bronchitis.


Assuntos
Adjuvantes Imunológicos/uso terapêutico , Linfócitos B/imunologia , Bronquite/imunologia , Linfócitos T/imunologia , Adolescente , Adulto , Linfócitos B/efeitos dos fármacos , Bronquite/tratamento farmacológico , Doença Crônica , Concanavalina A/farmacologia , Avaliação de Medicamentos , Humanos , Cetotifeno/uso terapêutico , Contagem de Leucócitos , Levamisol/uso terapêutico , Pessoa de Meia-Idade , Prodigiozan/uso terapêutico , Linfócitos T/efeitos dos fármacos
12.
Ter Arkh ; 60(3): 94-6, 1988.
Artigo em Russo | MEDLINE | ID: mdl-3388283

RESUMO

An optimum scheme of prodigiosan therapy was developed for patients with steroid-dependent bronchial asthma taking account of the hormonal and immunological status. First the drug was administered at a dose of 0.1 ml of 0.005% solution, then in 3-4 days the dose was increased (in good tolerance) up to 0.2-0.4-0.8-1.0 ml. After the first administration of the drug at a dose exceeding 0.1 ml herpes virus could be activated in the body. Course therapy producing a stimulating effect on the immune system, inhibited the occurrence of autoimmune manifestations, prolonged bronchial asthma remission, permitted the reduction of retention of a maintenance dose of glucocorticoids.


Assuntos
Reações Antígeno-Anticorpo/efeitos dos fármacos , Asma/tratamento farmacológico , Glucocorticoides , Polissacarídeos Bacterianos/uso terapêutico , Prodigiozan/uso terapêutico , Transtornos Relacionados ao Uso de Substâncias/tratamento farmacológico , Adulto , Asma/imunologia , Relação Dose-Resposta a Droga , Feminino , Humanos , Hipersensibilidade Tardia/imunologia , Imunidade Celular/efeitos dos fármacos , Leucócitos/efeitos dos fármacos , Leucócitos/imunologia , Masculino , Transtornos Relacionados ao Uso de Substâncias/imunologia , Fatores de Tempo
13.
Ter Arkh ; 60(11): 29-32, 1988.
Artigo em Russo | MEDLINE | ID: mdl-3238572

RESUMO

The therapeutic effectiveness of interferon inducers (prodigiozan and ibuprofen), the Soviet drug reaferon and their combined use in acute viral hepatitis type B was studied. Indications for their use resulted from lowered capacity of the body for interferonogenesis at the height of the disease. The above drugs stimulated cellular immunity, promoted more rapid disappearance of clinical symptoms of disease, and reduced the period of hospital treatment. A more marked therapeutic effect was noted in combined administration of reaferon and ibuprofen.


Assuntos
Hepatite B/tratamento farmacológico , Indutores de Interferon/uso terapêutico , Interferon Tipo I/uso terapêutico , Doença Aguda , Adolescente , Adulto , Idoso , Formação de Anticorpos/efeitos dos fármacos , Avaliação de Medicamentos , Quimioterapia Combinada , Hepatite B/imunologia , Humanos , Ibuprofeno/efeitos adversos , Ibuprofeno/uso terapêutico , Imunidade Celular/efeitos dos fármacos , Indutores de Interferon/efeitos adversos , Interferon Tipo I/efeitos adversos , Interferon alfa-2 , Interferon-alfa , Pessoa de Meia-Idade , Prodigiozan/efeitos adversos , Prodigiozan/uso terapêutico , Proteínas Recombinantes
14.
Antibiot Khimioter ; 39(2-3): 36-40, 1994.
Artigo em Russo | MEDLINE | ID: mdl-7979793

RESUMO

The diagnostic laparoscopy revealed ascending multifocal affections of the chlamydial origin in the organs of the small pelvis. It provided an objective information on the tuboperitoneal inflammation and made it possible to apply the adequate treatment. The surgical laparoscopy (adhesiotomy and salpingostomy) in the comprehensive treatment with the use of doxycycline and prodigiosan promoted the recovery of the female reproductive function.


Assuntos
Infecções por Chlamydia/tratamento farmacológico , Chlamydia trachomatis , Doxiciclina/uso terapêutico , Infertilidade Feminina/tratamento farmacológico , Peritonite/tratamento farmacológico , Salpingite/tratamento farmacológico , Adulto , Infecções por Chlamydia/complicações , Infecções por Chlamydia/diagnóstico , Doença Crônica , Quimioterapia Combinada , Feminino , Humanos , Infertilidade Feminina/diagnóstico , Infertilidade Feminina/etiologia , Laparoscopia , Peritonite/diagnóstico , Peritonite/etiologia , Prodigiozan/uso terapêutico , Salpingite/diagnóstico , Salpingite/etiologia , Aderências Teciduais
15.
Izv Akad Nauk Ser Biol ; (2): 227-34, 1993.
Artigo em Russo | MEDLINE | ID: mdl-8471974

RESUMO

Radioprotective and therapeutic effects of astazian and astazilide, the drugs of protozoan origin, were studied in comparison with known modifiers of biological reactions (bacterial polysaccharides, synthetic polypeptides) in combined radiation-thermal injuries (CRTI). The efficiency of drugs under examination was found to be time- and dose-dependent. Application of the drugs of protozoan nature 24 hours prior to or 1 hour following CRTI provided 30 to 50% survival of experimental animals for 30 days as compared to 4.5% in the group of untreated mice. Administration of the drugs 3-7 days following CRTI exerted no therapeutic effect.


Assuntos
Queimaduras/prevenção & controle , Eucariotos , Ácidos Graxos/uso terapêutico , Glucanos/uso terapêutico , Polissacarídeos/uso terapêutico , Lesões Experimentais por Radiação/prevenção & controle , Protetores contra Radiação/uso terapêutico , Animais , Queimaduras/tratamento farmacológico , Queimaduras/mortalidade , Avaliação Pré-Clínica de Medicamentos , Lipopolissacarídeos/uso terapêutico , Medições Luminescentes , Macrófagos/efeitos dos fármacos , Macrófagos/metabolismo , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Endogâmicos CBA , Prodigiozan/uso terapêutico , Pirogênios/uso terapêutico , Lesões Experimentais por Radiação/tratamento farmacológico , Lesões Experimentais por Radiação/mortalidade , Fatores de Tempo
16.
Vopr Onkol ; 35(1): 30-4, 1989.
Artigo em Russo | MEDLINE | ID: mdl-2521967

RESUMO

Decreased levels of neutrophils, Fc- and C3-expressing receptors, oxygen-dependent metabolism as well as antibody-dependent cytotoxicity of these cells to target cells were identified in advanced chronic myeloid leukemia, particularly, in blast crisis. Treatment with cytostatic agents resulted in further decrease in said parameters. However, treatment with prodigiozan was followed by improvement in cell functioning.


Assuntos
Adjuvantes Imunológicos , Citotoxicidade Celular Dependente de Anticorpos/efeitos dos fármacos , Leucemia Mielogênica Crônica BCR-ABL Positiva/tratamento farmacológico , Neutrófilos/efeitos dos fármacos , Polissacarídeos Bacterianos/uso terapêutico , Prodigiozan/uso terapêutico , Adulto , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Avaliação de Medicamentos , Quimioterapia Combinada , Feminino , Humanos , Leucemia Mielogênica Crônica BCR-ABL Positiva/imunologia , Masculino , Pessoa de Meia-Idade , Neutrófilos/imunologia , Receptores de Complemento/efeitos dos fármacos , Receptores de Complemento/imunologia , Receptores de Complemento 3b , Receptores Fc/efeitos dos fármacos , Receptores Fc/imunologia
17.
Klin Med (Mosk) ; 69(3): 77-80, 1991 Mar.
Artigo em Russo | MEDLINE | ID: mdl-2067345

RESUMO

Monotherapy with reaferon (alpha 2-interferon) versus prodigiosan plus ibuprofen combination was investigated in acute viral hepatitis B. The drugs were found to stimulate cellular immunity and to induce a decrease of total serum IgE levels. The effect of prodigiosan combined with ibuprofen proved more pronounced.


Assuntos
Hepatite B/terapia , Interferon Tipo I/uso terapêutico , Doença Aguda , Adolescente , Adulto , Idoso , Quimioterapia Combinada , Hepatite B/sangue , Humanos , Ibuprofeno/farmacologia , Ibuprofeno/uso terapêutico , Interferon alfa-2 , Interferon-alfa , Pessoa de Meia-Idade , Prodigiozan/farmacologia , Prodigiozan/uso terapêutico , Proteínas Recombinantes
18.
Lik Sprava ; (7): 73-6, 1993 Jul.
Artigo em Russo | MEDLINE | ID: mdl-8209540

RESUMO

64 patients with infectious-allergic bronchial asthma (IABA) were examined. 20 of them were co-administered paspat, 24 patients additionally received prodigiosan, 20 patients constituted control group and were given conventional treatment. Patients of all the groups were comparable in age, state of immunological reactivity of the body and severity of the disease. Immunomodulatory effect of the drugs, mainly of paspat, not only resulted in normalization of functional properties of granulocytes but also promoted liquidation of quantitative and functional IABA-conditioned immunodeficiency on the part of T- and B-lymphocytes, thus increasing effectiveness of the treatment in the whole.


Assuntos
Antígenos de Bactérias/uso terapêutico , Asma/terapia , Prodigiozan/uso terapêutico , Adolescente , Adulto , Asma/imunologia , Avaliação de Medicamentos , Quimioterapia Combinada , Feminino , Humanos , Imunidade Celular/efeitos dos fármacos , Masculino , Pessoa de Meia-Idade
19.
Khirurgiia (Mosk) ; (4): 86-90, 1991 Apr.
Artigo em Russo | MEDLINE | ID: mdl-2062077

RESUMO

From experience in the treatment of 326 patients with acute cholecystitis and concomitant obesity the authors discuss the causes of unfavourable outcomes and plan the means for improving the results. Postoperative suppuration of the wound occurred in 31.5% of cases, and was encountered most frequently in patients who underwent emergency and urgent operations. It was established that concomitant obesity in patients with acute cholecystitis is a factor raising the risk of postoperative pyo-inflammatory complications. The immune status was found to be significantly depressed. Preoperative immunoprophylaxis should be applied to prevent pyo-inflammatory complications after the operation.


Assuntos
Colecistite/complicações , Obesidade/complicações , Doença Aguda , Adulto , Idoso , Colecistectomia , Colecistite/imunologia , Colecistite/cirurgia , Emergências , Feminino , Humanos , Levamisol/uso terapêutico , Masculino , Pessoa de Meia-Idade , Obesidade/imunologia , Complicações Pós-Operatórias/prevenção & controle , Prodigiozan/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA